- E99 -

Fair Pricing Fair Access Future Innovation Learn more about how ICER is working to improve the US healthcare system Ongoing Assessments Recent Research. Easy access to our work Acute Pain Launch Price and Access Report Drug Approvals from 20232024 Multiple Sclerosis SPMS NonCystic Fibrosis Bronchiectasis Retinitis Pigmentosa Special Assessment to Inform CMS Drug Price Negotiation Breo Ellipta and Trelegy Ellipta Spinal Muscular Atrophy Featured News Insights. Learn about our latest work. Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Acute Pain Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to nonsystemic therapies suzetrigine has potential to be costsaving due to avoided future cases of opioid use disorder.